Financial assistance for your patients
Novo Nordisk believes in providing financial support through NovoCare®, a network that helps your eligible patients access co-pay savings, product assistance, and more.
Financial assistance for your patients
Novo Nordisk believes in providing financial support through NovoCare®, a network that helps your eligible patients access co-pay savings, product assistance, and more.

NovoCare® is designed for your patients
By creating a NovoCare® account, your patients can access:
- Product support programs that help with treatment costs
- Representatives who speak Spanish to better serve more patients
A Novo Nordisk Representative can help you connect patients with these resources. Or, you can send your patients to NovoCare.com
Insurance Coordination
Help with benefits verification
We can help you verify your patient’s benefits with QuickCheck™. Submit the form to receive a Summary of Benefits, generally within 4 hours,a from 9:00 am to 4:00 pm Eastern time.
- Download the QuickCheck™ Form
- Fax it to NovoCare® at 1-866-488-6576
aQuickCheck™ benefits verification can be completed within 4 hours only if all required information has been submitted.
Other support options for your patients
Eligible patients may be able to save on co-pay costsb or qualify for our product assistance program.c Use the tools below to get started and see how we can help patients using Esperoct®.

Interim Product Program
This limited program provides hemophilia therapy to qualifying patientsd during a coverage gap. Contact a NovoCare® Specialist by calling 1-844-668-6732.
Free Trial Prescription

Novo Nordisk is here to help your hemophilia A patients who want to make the switch to Esperoct®. Learn about our trial prescriptiond and product support programs.
To learn more about our trial prescription program, please call 1-844-668-6732 to speak with a NovoCare® Specialist.
bNovo Nordisk Hemophilia and Rare Bleeding Disorders Copay/Coinsurance Terms and Conditions:
Enrolled patients are eligible for up to $12,000 in co-pay/coinsurance assistance per calendar year for each NNI hemophilia or rare bleeding disorder product. Assistance is retroactive to 60 days. Patients must be commercially insured and may not be participating in any government, state, or federally funded medical or prescription benefit programs, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance. Uninsured, cash-paying patients are not eligible to participate. Patients are eligible to receive co-pay/coinsurance assistance on an annual basis (12 months). Offer good only in the USA, Puerto Rico, Guam, Saipan, and Virgin Islands with participating pharmacies and cannot be redeemed at government-subsidized clinics. Void where taxed, restricted, or prohibited by law. The Savings Card is no longer valid for residents of Massachusetts. Patient is responsible for complying with any insurance carrier co-payment disclosure requirements, including disclosing any savings received from this program. Re-confirmation of information may be requested periodically to ensure accuracy of data and compliance with terms. This is not an insurance program. Novo Nordisk reserves the right to rescind, revoke, or amend this offer without notice at any time. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible. Must have a current prescription for an FDA-approved indication.
cThe Novo Nordisk Patient Assistance Program (PAP) is administered by NovoCare®. To qualify for the PAP, patients must demonstrate financial need and must have attempted to find alternative reimbursement. Several factors are considered in evaluating financial need, including cost of living, size of household, and burden of total medical expenses. If the applicant qualifies under the PAP guidelines, a limited supply of the requested medication(s) will be shipped to the patient. Patients who qualify for PAP may be eligible to receive the prescribed Novo Nordisk product, for up to 1 year from the approval date. Product limits vary.
dPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit programs, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP and is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.
Questions about the NovoCare® program?
Selected Important Safety Information
Contraindications
- Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
- Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
Indications and Usage
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes
- Esperoct® is not indicated for the treatment of von Willebrand disease
Important Safety Information
Contraindications
- Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
- Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
- Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
Adverse Reactions
- The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions
Please click here for Prescribing Information.